Head-to-head evidence
Azvudine vs Emtricitabine/tenofovir disoproxil fumarate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Azvudine · FNC
Marketed by Henan Genuine Biotech
NCT04303598 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial testing whether azvudine achieves viral suppression as well as an established comparator, using a recognized clinical measure of HIV control, but results are not yet posted so the outcome is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Emtricitabine/tenofovir disoproxil fumarate · Truvada
Marketed by Gilead Sciences
NCT00323544 · Phase 3 · completed
This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07584122 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Azvudine's landscape · Emtricitabine/tenofovir disoproxil fumarate's landscape